Vanguard Personalized Indexing Management LLC Grows Stock Holdings in DaVita Inc. $DVA

Vanguard Personalized Indexing Management LLC grew its holdings in shares of DaVita Inc. (NYSE:DVA) by 13.0% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 6,214 shares of the company’s stock after purchasing an additional 713 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in DaVita were worth $885,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Aberdeen Group plc lifted its holdings in shares of DaVita by 16.5% during the second quarter. Aberdeen Group plc now owns 49,209 shares of the company’s stock valued at $7,010,000 after purchasing an additional 6,956 shares during the last quarter. KLP Kapitalforvaltning AS lifted its holdings in shares of DaVita by 1.1% during the second quarter. KLP Kapitalforvaltning AS now owns 28,614 shares of the company’s stock valued at $4,076,000 after purchasing an additional 300 shares during the last quarter. Ameritas Advisory Services LLC purchased a new position in shares of DaVita during the second quarter valued at approximately $47,000. Robeco Institutional Asset Management B.V. lifted its holdings in shares of DaVita by 485.5% during the second quarter. Robeco Institutional Asset Management B.V. now owns 44,809 shares of the company’s stock valued at $6,383,000 after purchasing an additional 37,156 shares during the last quarter. Finally, Truist Financial Corp raised its holdings in DaVita by 1.9% in the 2nd quarter. Truist Financial Corp now owns 8,646 shares of the company’s stock worth $1,232,000 after acquiring an additional 163 shares during the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider James O. Hearty sold 2,351 shares of the business’s stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total transaction of $352,650.00. Following the completion of the sale, the insider owned 26,038 shares of the company’s stock, valued at $3,905,700. The trade was a 8.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 1.50% of the stock is currently owned by insiders.

DaVita Trading Up 0.4%

Shares of DVA opened at $125.79 on Monday. The firm has a market cap of $8.99 billion, a PE ratio of 12.37, a P/E/G ratio of 0.90 and a beta of 1.13. The firm has a fifty day simple moving average of $132.49 and a two-hundred day simple moving average of $138.20. DaVita Inc. has a 1-year low of $122.93 and a 1-year high of $179.60.

DaVita (NYSE:DVA) last announced its earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share for the quarter, beating analysts’ consensus estimates of $2.70 by $0.25. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The business had revenue of $3.38 billion during the quarter, compared to analyst estimates of $3.36 billion. During the same period in the previous year, the business earned $2.00 EPS. The company’s quarterly revenue was up 6.1% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. As a group, research analysts forecast that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on DVA. Barclays decreased their price objective on shares of DaVita from $160.00 to $149.00 and set an “equal weight” rating for the company in a report on Thursday, October 9th. Bank of America decreased their price objective on shares of DaVita from $145.00 to $140.00 and set an “underperform” rating for the company in a report on Wednesday, September 10th. Truist Financial set a $140.00 price objective on shares of DaVita in a report on Tuesday, October 14th. Wall Street Zen lowered shares of DaVita from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of DaVita in a report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average target price of $153.25.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.